Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Posicor submitted for approval

April 19, 1996

New ETA antagonist from SmithKline Beecham: SB-225757

April 19, 1996

EMD-94246, promising endothelin antagonist for hypertension

April 19, 1996

Zanidip approved for marketing in U.K.

April 19, 1996

CP-191166, angiotensin II antagonist from Pfizer

April 19, 1996

YM-087 in phase I for CHF

April 12, 1996

New angiotensin II antagonists from Kotobuki

April 12, 1996

Teijin reveals new agent for restenosis

April 5, 1996

New endothelin antagonists from RPR reported at 211th ACS

April 5, 1996

New agent for sudden cardiac death in phase I at Nortran

April 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 5, 2025.
CMS vows to put more emphasis on MA plans’ prior authorization
BioWorld MedTech
Physicians aren’t the only ones who see prior authorization (PA) practices as a significant problem, but John Brooks, deputy administrator at CMS, told a med tech...
100 days of uncertainty
BioWorld
The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
Associate degree: PTC’s hints of phase II HD efficacy studied
BioWorld
PTC Therapeutics Inc. CEO Matthew Klein said the firm “achieved all we set out to [achieve] in phase II” with PTC-518 in Huntington’s disease (HD), but it wasn’t...